Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?

M J Gandal1, R L Anderson, E N Billingslea

  • 1Translational Neuroscience Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA. mgandal@mail.med.upenn.edu

Insights

Reduced NMDA-receptor (NMDAR) function is linked to neuropsychiatric conditions like schizophrenia and autism. This study shows NMDAR hypofunction in mice mimics autism phenotypes, suggesting a shared pathophysiology for these disorders.

Area of Science:

  • Neuroscience
  • Genetics
  • Psychiatry

Background:

  • Reduced NMDA-receptor (NMDAR) function is implicated in schizophrenia and autism spectrum disorders (ASD).
  • Mouse models are crucial for understanding the direct contribution of NMDAR dysfunction to disease phenotypes.

Purpose of the Study:

  • To investigate if NMDAR hypofunction is associated with autism spectrum disorder (ASD)-like phenotypes.
  • To compare the behavioral and electrophysiological abnormalities in a mouse model with those seen in clinical studies of autism and schizophrenia.

Main Methods:

  • Utilized a mouse model with reduced expression of the NR1 subunit (NR1(neo-/-) mice).
  • Assessed behavioral paradigms relevant to ASD, including social interaction, ultrasonic vocalizations, and repetitive behaviors.
  • Conducted auditory electrophysiological tests, including prepulse inhibition (PPI) and evoked response latency.

Main Results:

  • NR1(neo-/-) mice exhibited behavioral deficits consistent with core ASD symptoms.
  • NMDAR disruption recapitulated clinical endophenotypes such as reduced PPI, delayed auditory evoked response N1 latency, and decreased gamma synchrony.
  • Auditory electrophysiological abnormalities in mice more closely resembled those in clinical autism studies than schizophrenia studies.

Conclusions:

  • NMDAR hypofunction may be associated with a continuum of neuropsychiatric diseases, including both schizophrenia and ASD.
  • Neural synchrony abnormalities suggest an imbalance in glutamatergic and GABAergic signaling.
  • Behavioral and neural synchrony phenotypes offer potential targets for preclinical screening of novel therapeutics.